Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia

BACKGROUND: Recent evidence suggests that resistance to CD19 chimeric antigen receptor (CAR)-modified T cell therapy may be due to the presence of CD19 isoforms that lose binding to the single-chain variable fragment (scFv) in current use. As such, further investigation of CARs recognize different e...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Runxia, Liu, Fang, Zou, Dehui, Xu, Yingxi, Lu, Yang, Liu, Bingcheng, Liu, Wei, Chen, Xiaojuan, Liu, Kaiqi, Guo, Ye, Gong, Xiaoyuan, Lv, Rui, Chen, Xia, Zhou, Chunlin, Zhong, Mengjun, Wang, Huijun, Wei, Hui, Mi, Yingchang, Qiu, Lugui, Lv, Lulu, Wang, Min, Wang, Ying, Zhu, Xiaofan, Wang, Jianxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487702/
https://www.ncbi.nlm.nih.gov/pubmed/32894185
http://dx.doi.org/10.1186/s13045-020-00953-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487702/
https://www.ncbi.nlm.nih.gov/pubmed/32894185
http://dx.doi.org/10.1186/s13045-020-00953-8

Ejemplares similares